UPB Upstream Bio Earnings and EPS analysis

  1. Stocks
  2. Healthcare
  3. NASDAQ: UPB
  4. Earnings
?
Relative Growth: Rel. Growth: 46
Relative Strength: Rel. Strength: 7
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 25

EPS in 2026 (TTM): -$2.9

Last Report Period Date: Mar 31, 2026

As of June this year, based on Upstream Bio's latest financial report, the company's current EPS (TTM) is -$2.9. Upstream Bio's earnings per share in 2025 came in at -$2.66, marking an increase from -$5.58 in 2024. Upstream Bio's EPS for the quarterly period ending on Mar 31, 2026 was -$0.75.

UPB earnings history

Historical annual and quarterly earnings per share (EPS) data for Upstream Bio
EPS (TTM)
-$2.9
EPS Growth YoY (Quarterly)
-47.1%
EPS (Quarterly)
-$0.75
EPS Growth (Quarterly)
3.8%

The yearly EPS in 2025 was -$2.66, an increase of 52.3% compared to -$5.58 recorded in 2024. The quarterly EPS for the period ending Mar 31, 2026, was -$0.75, marking a 47.1% decline compared to the same quarter last year. UPB's TTM EPS is -$2.9 as of March 2026. Upstream Bio's EPS for 2024 was -$5.58, a 56.9% rise from 2023.

UPB earnings chart

UPB EPS growth history

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
-47.1%
EPS growth YoY
52.3%
EPS growth 3Y avg
N/A
EPS growth 5Y avg
N/A

Over the past 12 months, Upstream Bio has recorded an earnings per share growth of -47.1% (YoY, quarterly).

UPB Earnings Waterfall

Breakdown of revenue, profit and net income for Upstream Bio

UPB Earnings vs Peers

What are the earnings of UPB compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
REGN Regeneron Pharmaceuticals Inc 14.76 5.3% 2.1% 5.7%
GILD Gilead Sciences Inc 17.41 1,700% 23.2% 132.8%
BIIB Biogen Inc 21.02 -21.2% -25% -18.7%
AMGN Amgen Inc 23.87 88.1% 5.6% 2.9%
VRTX Vertex Pharmaceuticals Inc 25.97 843.3% 6% 8.2%
ILMN Illumina Inc 30.44 171.1% N/A 4.1%
MRNA Moderna Inc N/A 21.8% N/A N/A
CRSP CRISPR Therapeutics AG N/A -49.1% N/A N/A
EDIT Editas Medicine Inc N/A 37.5% N/A N/A
UPB Upstream Bio Inc. N/A 52.3% N/A N/A

All data is based on quarterly TTM periods, unless otherwise specified.